CDK4 and breast carcinoma: This study extends our understanding of real-world CDK4 and 6 inhibitor use in Japan, providing insight into current treatment practices for HR+, HER2− advanced breast cancer, specifically in relation to treatment patterns of CDK4 and 6 inhibitor use and their clinical outcomes.